IKKβ-IN-7 是一种 IC50 值为 9.44 μM 的 IKKβ 抑制剂,可诱导 DNA 损伤、S 期细胞周期阻滞、ROS 积累、线粒体膜电位丢失及凋亡 (apoptosis),抑制 p65 和 IκBα 的磷酸化,阻断 p65 的核转位,并调控 NF-κB 调控的基因,从而抑制异种移植模型中的肿瘤生长,对结直肠癌具有活性且对正常细胞的细胞毒性较低,可用于结直肠癌的研究。
产品编号: MS-C99628 CAS No.: 3117527-92-8 分子式: C45H42N2O11 分子量: 786.82
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

IKKβ-IN-7 是一种 IC50 值为 9.44 μM 的 IKKβ 抑制剂,可诱导 DNA 损伤、S 期细胞周期阻滞、ROS 积累、线粒体膜电位丢失及凋亡 (apoptosis),抑制 p65 和 IκBα 的磷酸化,阻断 p65 的核转位,并调控 NF-κB 调控的基因,从而抑制异种移植模型中的肿瘤生长,对结直肠癌具有活性且对正常细胞的细胞毒性较低,可用于结直肠癌的研究。

生物实验数据

生物活性 IKKβ-IN-7 is an IKKβ inhibitor with an IC50 value of 9.44 μM that induces DNA damage, S-phase cell cycle arrest, ROS accumulation, loss of mitochondrial membrane potential, and apoptosis, inhibits the phosphorylation of p65 and IκBα, blocks the nuclear translocation of p65, and modulates NF-κB-regulated genes, thereby suppressing tumor growth in xenograft models, exhibiting activity against colorectal cancer with low cytotoxicity to normal cells, and can be used for research on colorectal cancer.
IC50 & Target IKKβ:9.44 μM
体外研究
(In Vitro)

IKKβ-IN-7 (6i2) (给药 24 小时) 可强效抑制多种癌细胞系的增殖,包括 A549 细胞 (IC50 = 5.11 μM)、HepG2 细胞 (IC50 = 9.81 μM)、HCT-116 细胞 (IC50 = 1.08 μM)、HT-29 细胞 (IC50 = 4.17 μM)、RKO 细胞 (IC50 = 4.72 μM) 以及 CT-26 细胞 (IC50 = 0.86 μM),同时对永生化人肝上皮正常细胞 THLE-2 的细胞毒性较低 (IC50 > 16 μM)。
IKKβ-IN-7 (给药 1 小时) 可直接抑制 IKKβ 激酶活性,其 IC50 为 9.44 μM。
IKKβ-IN-7 (2.0 μM; 30 min) 可强效抑制 Topo I 活性,在 37°C 孵育 30 min 后,2.0 μM 浓度下的抑制率达 96.84%。
IKKβ-IN-7 (0.5-2.0 μM; 24 h) 在体外以剂量依赖的方式对 HCT-116 细胞产生多种生物学效应:通过增加 γ-H2AX 表达诱导 DNA 损伤并降低 Topo I 蛋白水平 (2.0 μM 时效果最强);剂量依赖性地抑制 IκBα 和 p65 的磷酸化,从而抑制 NF-κB 通路的激活;抑制 p65 核转位而不改变 p65 总蛋白水平;调节 Bcl-2 家族蛋白的表达 (增加促凋亡蛋白 Bax 并降低抗凋亡蛋白 Bcl-2、Bcl-xl 和 Mcl-1),表明诱导线粒体介导的细胞凋亡;在 2.0 μM 时诱导细胞凋亡,凋亡率为 68.29%;在 2.0 μM 浓度下可诱导 S 期细胞周期阻滞;增加细胞内 ROS 水平;降低线粒体膜电位。
IKKβ-IN-7 (0.5-2.0 μM; 24 h, 48 h) 可呈剂量依赖性抑制人结直肠癌 HCT-116 细胞的伤口愈合迁移。

Western Blot Analysis

Cell Line: human colorectal carcinoma HCT-116 cells
Concentration: 0.5, 1, 2.0 μM
Incubation Time: 24 h
Result: Decreased Topo I levels by more than 50% at 2.0 μM, and increased γ-H2AX expression by 2–3-fold in a dose-dependent manner compared with untreated controls.
Reduced the phosphorylation levels of IκBα and p65 gradually to less than 0.5-fold of control levels as concentration increased from 0.5 to 2.0 μM.
Left total p65 protein levels unchanged, but decreased nuclear p65 levels significantly and increased cytoplasmic p65 levels in a dose-dependent manner compared with controls.
Increased Bax expression in a dose-dependent manner, while significantly reduced the expression of anti-apoptotic proteins Bcl-2, Bcl-xL and Mcl-1 in a dose-dependent manner.

Apoptosis Analysis

Cell Line: human colorectal carcinoma HCT-116 cells
Concentration: 0.5, 1, 2.0 μM
Incubation Time: 24 h
Result: Induced apoptosis rates of 39.45% (0.5 μM), 58.14% (1.0 μM), and 68.29% (2.0 μM), compared to 8.86% in untreated controls.

Cell Cycle Analysis

Cell Line: human colorectal carcinoma HCT-116 cells
Concentration: 0.5, 1, 2.0 μM
Incubation Time: 24 h
Result: Induced S-phase arrest, with the proportion of cells in S phase reaching 44.6% at 2.0 μM, in a dose-dependent manner.

Cell Migration Assay

Cell Line: human colorectal carcinoma HCT-116 cells
Concentration: 0.5, 1, 2.0 μM
Incubation Time: 24 h; 48 h
Result: Inhibited wound healing in a dose-dependent manner, with wound healing rates of 25.23% (24 h, 0.5 μM), 5.70% (24 h, 1.0 μM), 4.69% (24 h, 2.0 μM), 69.67% (48 h, 0.5 μM), 54.78% (48 h, 1.0 μM), and 18.35% (48 h, 2.0 μM), compared to 43.05% (24 h) and 94.61% (48 h).
体内研究
(In Vivo)

IKKβ-IN-7 (6i2) (2.5-60 mg/kg;腹腔注射;每 2 天 1 次,连续 2 天) 在 CT-26 异种移植模型中显示出显著的体内抗肿瘤功效,且安全性良好、急性毒性低,同时具有一定的血浆稳定性并能持续释放 SN-38 (MS-K87916)。

Animal Model: Female immunocompetent BALB/c mice (5-6 weeks old) were subcutaneously injected with CT-26 cells (3 × 106 cells per mouse in 100 μL sterile PBS)
Dosage: 2.5 mg/kg, 5 mg/kg
Administration: Intraperitoneal (IP) injection; once every other day
Result: Exhibited potent antitumor efficacy with tumor growth inhibition (TGI) rates of 68.81% (2.5 mg/kg) and 95.41% (5 mg/kg).
No significant body weight loss or animal mortality observed during the treatment period.
H&E staining of major organs (heart, liver, spleen, lung, kidney) revealed no obvious morphological abnormalities.
Superior safety profile compared to 10-HCPT (which caused inflammatory cell infiltration in spleen and glomerular atrophy in kidney at 2.5 mg/kg).
Animal Model: Female immunocompetent BALB/c mice (20.0 g) were used for acute toxicity test
Dosage: 2.5 mg/kg, 5 mg/kg, 10 mg/kg, 20 mg/kg, 40 mg/kg, 60 mg/kg
Administration: Intraperitoneal (IP) injection; once daily; each dose administered for 2 consecutive days (total 12 days)
Result: No animal death observed at doses up to 20 mg/kg.
Minimal lethal dose (MLD) and median lethal dose (LD50) were determined based on survival status, with lower toxicity than 10-HCPT (which caused mortality at 5 mg/kg).

化学信息

分子量 786.82
分子式 C45H42N2O11
CAS No. 3117527-92-8

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础